Catch up on the top stories in optometry during the week of September 8-September 12.

A total of 293 optometrists, practice owners, and managers were involved in the survey.

Researchers conducted this study to determine how often and why spontaneous soft drusen regresses without atrophy in patients who had intermediate or atrophic age-related macular degeneration.

Panelists discuss how they use staging systems, such as the Mackie classification (mild, moderate, severe), and incorporate corneal sensitivity testing into comprehensive eye exams for better risk stratification.

Panelists discuss how early recognition of stage 1 neurotrophic keratitis (NK) leads to better treatment outcomes and how to identify key risk factors, including diabetes, herpes infections, and long-term glaucoma medication use.

Researchers will investigate a gene in the eye that is crucial for normal vision, but can cause retinal diseases when mutated that often lead to blindness.

wavelight plus was first launched in China, with several European and Asia-Pacific markets following suit.

Award winners will be recognized during the Academy 2025 meeting in Boston, Massachusetts, running from October 8 to 11.

Xiidra is a prescription eye drop used to treat the signs and symptoms of dry eye disease (DED) and works by targeting the source of inflammation.

The trial will evaluate the solution in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision.

The lens portfolio includes spherical, aspheric, toric, multifocal, multifocal toric, reverse geometry, and keratoconic contact lenses.

Catch up on the top stories in optometry during the week of September 1-September 5.

Dan Ignaszewski, executive director of the Alliance for Eye and Vision Research and the National Alliance for Eye and Vision Research, provides insight into the new campaign and how to get involved.

Findings from the retrospective, observational study support the potential anti-inflammatory benefits of the drug class.